Arcutis Biotherapeutics, a leading clinical-stage biopharmaceutical company, recently showcased its impressive performance and outlined upcoming regulatory and pipeline milestones at TD Cowen’s 46th Annual Healthcare Conference. The company’s executives highlighted the success of ZORYVE and emphasized key achievements in the fourth quarter and full-year 2025.
Chief Executive Officer Frank Watanabe expressed satisfaction with the company’s performance, citing fourth-quarter net revenue of $127.5 million and total revenue of $372 million for the year. Watanabe noted that these results exceeded consensus expectations and highlighted the doubling of prescriptions in 2025.
Chief Commercial Officer Todd Edwards provided insights into the company’s growth, pointing out a 29% quarter-over-quarter increase in net revenue in Q4, with all products in the portfolio experiencing growth. Edwards also discussed the company’s plans to expand its dermatology sales force by 30 representatives to enhance customer engagement.
Management emphasized the growth potential of ZORYVE as a conversion story away from topical steroids. Edwards shared data showing a significant market opportunity with 24 million topical prescriptions written in dermatology for inflammatory skin diseases. He highlighted ZORYVE’s leading position in the nonsteroidal topical market and its capturing of a substantial market share.
Looking ahead, Arcutis aims to strengthen its primary care and pediatric sales capabilities by hiring and onboarding a dedicated team to complement its existing dermatology team. The company plans to have these teams operational by July 1, with a focus on increasing market penetration and expanding access to healthcare providers.
In terms of product development, Arcutis is evaluating additional uses for ZORYVE beyond its current indications, with ongoing Phase II studies in hidradenitis suppurativa and vitiligo. The company also plans to introduce ARQ-234, a novel approach for atopic dermatitis, into clinical trials this quarter.
In conclusion, Arcutis Biotherapeutics continues to demonstrate strong performance and a commitment to innovation in the treatment of immuno-inflammatory skin diseases. With a focus on expanding market access, enhancing product offerings, and advancing its pipeline, the company is well-positioned for continued growth and success in the biopharmaceutical industry.
